PF-07038124
Pfizer
['psoriasis', 'pf-07038124']
congress #eadvcongress | lawrence eichenfield presented results from a phase 2a study of pf-07038124, a phosphodiesterase-4 inhibitor, for use in plaque psoriasis or ad. treated pts showed improvement in iga response rate &amp; reduction in pasi score, compared to the vehicle control 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.